X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (17) 17
index medicus (16) 16
female (14) 14
male (14) 14
middle aged (14) 14
hematology (13) 13
aged (12) 12
adult (11) 11
life sciences (8) 8
aged, 80 and over (7) 7
antineoplastic combined chemotherapy protocols - administration & dosage (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
rituximab (7) 7
treatment outcome (7) 7
abridged index medicus (6) 6
adolescent (6) 6
cancer (6) 6
cyclophosphamide - administration & dosage (6) 6
disease-free survival (6) 6
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
chemotherapy (5) 5
doxorubicin - administration & dosage (5) 5
follow-up studies (5) 5
non-hodgkins-lymphoma (5) 5
prednisone - administration & dosage (5) 5
survival (5) 5
survival rate (5) 5
vincristine - administration & dosage (5) 5
young adult (5) 5
[ sdv.imm ] life sciences [q-bio]/immunology (4) 4
antibodies, monoclonal, murine-derived - administration & dosage (4) 4
cyclophosphamide - adverse effects (4) 4
lymphoma, large b-cell, diffuse - drug therapy (4) 4
oncology (4) 4
prognosis (4) 4
prospective studies (4) 4
retrospective studies (4) 4
transplantation, autologous (4) 4
[ sdv.can ] life sciences [q-bio]/cancer (3) 3
antibodies, monoclonal - administration & dosage (3) 3
clinical trials (3) 3
doxorubicin - adverse effects (3) 3
efficacy (3) 3
expression (3) 3
immunology (3) 3
leukemia, lymphocytic, chronic, b-cell - mortality (3) 3
leukemia, lymphocytic, chronic, b-cell - therapy (3) 3
lymphomas (3) 3
multicenter (3) 3
open-label (3) 3
patients (3) 3
prednisone - adverse effects (3) 3
stem-cell transplantation (3) 3
therapy (3) 3
time factors (3) 3
[sdv.imm]life sciences [q-bio]/immunology (2) 2
analysis (2) 2
antibodies, monoclonal - adverse effects (2) 2
antibodies, monoclonal - therapeutic use (2) 2
antineoplastic agents, immunological - administration & dosage (2) 2
antineoplastic agents, immunological - adverse effects (2) 2
antineoplastic agents, immunological - therapeutic use (2) 2
bone marrow transplantation (2) 2
bone-marrow-transplantation (2) 2
care and treatment (2) 2
child (2) 2
combined modality therapy (2) 2
cyclophosphamide (2) 2
cyclophosphamide - therapeutic use (2) 2
cytarabine - administration & dosage (2) 2
dexamethasone - administration & dosage (2) 2
diagnosis (2) 2
doxorubicin (2) 2
doxorubicin - therapeutic use (2) 2
drug administration schedule (2) 2
elderly-patients (2) 2
gene (2) 2
hematopoietic stem cell transplantation (2) 2
hemic and lymphatic diseases (2) 2
high-dose therapy (2) 2
lenalidomide (2) 2
medical research (2) 2
medicine, experimental (2) 2
minimal residual disease (2) 2
monoclonal antibodies (2) 2
multiple myeloma - drug therapy (2) 2
multiple myeloma - genetics (2) 2
multivariate analysis (2) 2
myelodysplastic syndrome (2) 2
neoplasm staging (2) 2
neutropenia - chemically induced (2) 2
nitrogen intake (2) 2
prednisone (2) 2
prednisone - therapeutic use (2) 2
proportional hazards models (2) 2
recurrence (2) 2
remission induction (2) 2
research (2) 2
response criteria (2) 2
risk assessment (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9806, pp. 1858 - 1867
Summary Background The outcome of diffuse large B-cell lymphoma has been substantially improved by the addition of the anti-CD20 monoclonal antibody rituximab... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | MULTICENTER | RESPONSE CRITERIA | AGGRESSIVE LYMPHOMAS | POOR-PROGNOSIS | NON-HODGKINS-LYMPHOMA | REGIMEN | YOUNG-PATIENTS | ELDERLY-PATIENTS | DES-LYMPHOMES | TRANSPLANTATION | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Dose-Response Relationship, Drug | Young Adult | Vindesine - adverse effects | Adult | Female | Prednisolone | Doxorubicin - administration & dosage | Severity of Illness Index | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Risk Assessment | Rituximab | Treatment Outcome | Bleomycin - administration & dosage | Bleomycin - adverse effects | Vincristine | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Adolescent | Survival Analysis | Vindesine - administration & dosage | Doxorubicin - adverse effects | Chemotherapy | Physiological aspects | Lymphomas | B cells | Drug therapy | Methods | Cancer | Dehydrogenases | Toxicity | Population studies | Doxorubicin | Evidence-based medicine | Hepatitis | Randomization | Bleomycin | Motivation | Drug dosages | Neutropenia | Cell survival | Hematology | Prednisone | Survival | Patients | Lymphoma | Cyclophosphamide | Lymphocytes B | Monoclonal antibodies | CD20 antigen | Tumors | B-cell lymphoma | Clinical trials | Public speaking | Grants | Clinical medicine | Side effects | lymphoma | survival | International standardization | chemotherapy
Journal Article
Transfusion clinique et biologique, ISSN 1246-7820, 11/2018, Volume 25, Issue 4, pp. 335 - 335
L’hémosidérose post-transfusionnelle reste sous déclarée en France, 39 FEIR en 2016, 0,58 % des FEIR rapport ANSM aucune déclaration au CHANGE. Dans l’étude... 
Journal Article
Transfusion clinique et biologique, ISSN 1246-7820, 11/2018, Volume 25, Issue 4, p. 335
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1016/j.tracli.2018.08.027 Sous... 
Journal Article
Transfusion clinique et biologique, ISSN 1246-7820, 11/2016, Volume 23, Issue 4, pp. 306 - 306
Décharger le SAU des transfusions pouvant être faites dans les unités de soins. Analyse de 90 séjours de patients transfusés au SAU du 01/01/2014 au... 
Journal Article
Transfusion clinique et biologique, ISSN 1246-7820, 11/2016, Volume 23, Issue 4, p. 306
Decharger le SAU des transfusions pouvant etre faites dans les unites de soins. 
Journal Article
American Journal of Hematology, ISSN 0361-8609, 04/2016, Volume 91, Issue 4, pp. 366 - 370
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2017, Volume 35, Issue 22, pp. 2473 - 2481
Journal Article
Journal Article
Journal Article
Haematologica, ISSN 0390-6078, 08/2010, Volume 95, Issue 8, pp. 1350 - 1357
Journal Article
Blood, ISSN 0006-4971, 06/2011, Volume 117, Issue 23, pp. 6109 - 6119
Journal Article